Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Phase 1/2a Study of the Safety and Efficacy of Melflufen and Dexamethasone in Combination With Either Bortezomib or Daratumumab in Patients With Relapsed or Relapsed-Refractory Multiple Myeloma

NCT03481556 is registered in ClinicalTrials.gov with Oncopeptides AB as lead sponsor.

NCT NCT03481556
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03481556 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Phase 1/2a Study of the Safety and Efficacy of Melflufen and Dexamethasone in Combination With Either Bortezomib or Daratumumab in Patients With Relapsed or Relapsed-Refractory Multiple Myeloma
Lead sponsor
Oncopeptides AB
Phase
Phase 1/2
Overall status
Terminated
Start date
April 12, 2018
Completion date
February 2, 2022
Enrollment
56 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma